a Laboratorio de Bioquímica y Biología Molecular, Centro de Química del Instituto de Ciencias (ICUAP), Edificio 103F, Ciudad Universitaria, Benemérita Universidad Autónoma de Puebla , Puebla , Mexico.
b Laboratorio de Biología Celular, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Metepec , Puebla , Mexico.
Expert Opin Ther Pat. 2019 Aug;29(8):587-593. doi: 10.1080/13543776.2019.1637422. Epub 2019 Jul 4.
: TIM3 and PD-1 are checkpoint inhibitors in cancer that coordinate the downregulation of the proliferation of antigen-specific lymphocytes. There is a great need to discover and develop new therapies focused on inhibiting the action of TIM3 and PD-1 and consequently improving the immune response in the various types of cancer. The authors of patent EP3356411A1 propose several anti-TIM3/anti-PD-1 bispecific antibodies, as well as the method for producing them and their pharmacological application in the treatment of cancer. : Patent EP3356411A1 describes a method by producing anti-TIM3/anti-PD-1 bispecific antibodies and their potential in cancer treatment. : Data supporting the patent demonstrate the ability by producing anti-TIM3/anti-PD-1 bispecific antibodies. Although the proposed methodology is very interesting and promising, further studies are necessary to assess the clinical applicability of the inventions on cancer.
: TIM3 和 PD-1 是癌症中的检查点抑制剂，它们协调抗原特异性淋巴细胞增殖的下调。非常需要发现和开发新的治疗方法，专注于抑制 TIM3 和 PD-1 的作用，从而改善各种类型癌症中的免疫反应。专利 EP3356411A1 的作者提出了几种抗 TIM3/抗 PD-1 双特异性抗体，以及生产它们的方法及其在癌症治疗中的药理学应用。 : EP3356411A1 专利描述了一种生产抗 TIM3/抗 PD-1 双特异性抗体的方法及其在癌症治疗中的潜力。 : 支持专利的数据证明了生产抗 TIM3/抗 PD-1 双特异性抗体的能力。尽管所提出的方法学非常有趣和有前途，但仍需要进一步的研究来评估这些关于癌症的发明在临床上的适用性。
